Mackay Shields LLC Sells 340 Shares of CME Group Inc (NASDAQ:CME)

Mackay Shields LLC trimmed its position in CME Group Inc (NASDAQ:CME) by 0.5% during the third quarter, Holdings Channel reports. The institutional investor owned 66,519 shares of the financial services provider’s stock after selling 340 shares during the quarter. Mackay Shields LLC’s holdings in CME Group were worth $14,058,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. First American Trust FSB boosted its position in shares of CME Group by 1.2% in the 2nd quarter. First American Trust FSB now owns 17,342 shares of the financial services provider’s stock worth $3,366,000 after purchasing an additional 212 shares during the last quarter. Burns J W & Co. Inc. NY boosted its position in shares of CME Group by 0.4% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 18,165 shares of the financial services provider’s stock worth $3,526,000 after purchasing an additional 80 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of CME Group by 1.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 22,468 shares of the financial services provider’s stock worth $4,361,000 after purchasing an additional 330 shares during the last quarter. Contravisory Investment Management Inc. boosted its position in shares of CME Group by 22.9% in the 2nd quarter. Contravisory Investment Management Inc. now owns 344 shares of the financial services provider’s stock worth $67,000 after purchasing an additional 64 shares during the last quarter. Finally, Argus Investors Counsel Inc. lifted its holdings in CME Group by 106.3% during the second quarter. Argus Investors Counsel Inc. now owns 5,164 shares of the financial services provider’s stock worth $1,002,000 after acquiring an additional 2,661 shares in the last quarter. Hedge funds and other institutional investors own 84.80% of the company’s stock.

In other CME Group news, Director Daniel R. Glickman sold 500 shares of CME Group stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $216.01, for a total value of $108,005.00. Following the sale, the director now owns 14,593 shares of the company’s stock, valued at approximately $3,152,233.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Tully sold 7,200 shares of CME Group stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $223.13, for a total value of $1,606,536.00. Following the completion of the sale, the insider now directly owns 19,923 shares in the company, valued at approximately $4,445,418.99. The disclosure for this sale can be found here. Insiders sold a total of 15,136 shares of company stock worth $3,319,698 in the last three months. Company insiders own 1.20% of the company’s stock.

CME has been the topic of several recent analyst reports. Wells Fargo & Co lifted their target price on CME Group from $200.00 to $205.00 and gave the stock a “market perform” rating in a report on Thursday, October 31st. Deutsche Bank lifted their target price on CME Group from $224.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, August 9th. ValuEngine lowered CME Group from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. BidaskClub lowered CME Group from a “buy” rating to a “hold” rating in a report on Friday, October 18th. Finally, Citigroup lifted their target price on CME Group from $220.00 to $240.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $203.36.

CME stock opened at $198.59 on Thursday. The business’s 50-day moving average price is $209.04 and its two-hundred day moving average price is $201.37. The company has a current ratio of 1.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.14. The firm has a market cap of $70.55 billion, a PE ratio of 29.12, a P/E/G ratio of 3.87 and a beta of 0.18. CME Group Inc has a 1-year low of $161.05 and a 1-year high of $224.91.

CME Group (NASDAQ:CME) last released its quarterly earnings results on Wednesday, October 30th. The financial services provider reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.75 by $0.15. CME Group had a return on equity of 9.54% and a net margin of 40.93%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter last year, the business posted $1.45 EPS. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. On average, analysts forecast that CME Group Inc will post 6.91 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Tuesday, December 10th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.51%. CME Group’s dividend payout ratio is 43.99%.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.

Further Reading: What is Put Option Volume?

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.